The upcoming May regulatory calendar appears relatively light, with only five key FDA decisions expected. Despite the limited number of events, the slate includes several potentially meaningful label expansions across major therapeutic areas.
Let's take a closer look at what's ahead for the month.
argenx SE (ARGX)
The FDA decision on the expanded use of argenx's VYVGART for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia gravis is due on May 10, 2026.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.